How do substance use disorders compare to other psychiatric conditions on structural brain abnormalities? A cross-disorder meta-analytic comparison using the ENIGMA consortium findings.
addiction
alcohol
cannabis
structural neuroimaging
Journal
Human brain mapping
ISSN: 1097-0193
Titre abrégé: Hum Brain Mapp
Pays: United States
ID NLM: 9419065
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
revised:
19
05
2020
received:
21
01
2020
accepted:
16
06
2020
pubmed:
10
7
2020
medline:
29
3
2022
entrez:
10
7
2020
Statut:
ppublish
Résumé
Alcohol use disorder (AUD) and cannabis use disorder (CUD) are associated with brain alterations particularly involving fronto-cerebellar and meso-cortico-limbic circuitry. However, such abnormalities have additionally been reported in other psychiatric conditions, and until recently there has been few large-scale investigations to compare such findings. The current study uses the Enhancing Neuroimaging Genetics through Meta-Analysis (ENIGMA) consortium method of standardising structural brain measures to quantify case-control differences and to compare brain-correlates of substance use disorders with those published in relation to other psychiatric disorders. Using the ENIGMA protocols, we report effect sizes derived from a meta-analysis of alcohol (seven studies, N = 798, 54% are cases) and cannabis (seven studies, N = 447, 45% are cases) dependent cases and age- and sex-matched controls. We conduct linear analyses using harmonised methods to process and parcellate brain data identical to those reported in the literature for ENIGMA case-control studies of major depression disorder (MDD), schizophrenia (SCZ) and bipolar disorder so that effect sizes are optimally comparable across disorders. R elationships between substance use disorder diagnosis and subcortical grey matter volumes and cortical thickness were assessed with intracranial volume, age and sex as co-variates . After correcting for multiple comparisons, AUD case-control meta-analysis of subcortical regions indicated significant differences in the thalamus, hippocampus, amygdala and accumbens, with effect sizes (0.23) generally equivalent to, or larger than |0.23| those previously reported for other psychiatric disorders (except for the pallidum and putamen). On measures of cortical thickness, AUD was associated with significant differences bilaterally in the fusiform gyrus, inferior temporal gyrus, temporal pole, superior frontal gyrus, and rostral and caudal anterior cingulate gyri. Meta-analysis of CUD case-control studies indicated reliable reductions in amygdala, accumbens and hippocampus volumes, with the former effect size comparable to, and the latter effect size around half of that reported for alcohol and SCZ. CUD was associated with lower cortical thickness in the frontal regions, particularly the medial orbitofrontal region, but this effect was not significant after correcting for multiple testing. This study allowed for an unbiased cross-disorder comparison of brain correlates of substance use disorders and showed alcohol-related brain anomalies equivalent in effect size to that found in SCZ in several subcortical and cortical regions and significantly greater alterations than those found in MDD in several subcortical and cortical regions. Although modest, CUD results overlapped with findings reported for AUD and other psychiatric conditions, but appear to be most robustly related to reduce thickness of the medial orbitofrontal cortex.
Identifiants
pubmed: 32643841
doi: 10.1002/hbm.25114
pmc: PMC8675406
doi:
Types de publication
Comparative Study
Journal Article
Meta-Analysis
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
399-413Subventions
Organisme : NCRR NIH HHS
ID : UL1 RR024925
Pays : United States
Organisme : NIH HHS
ID : UL1-RR24925-01
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : NIDA NIH HHS
ID : PL30-1DA024859-01
Pays : United States
Organisme : NIDA NIH HHS
ID : 1R21DA038381
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH116147
Pays : United States
Organisme : NIDA NIH HHS
ID : PL1 DA024859
Pays : United States
Organisme : NIBIB NIH HHS
ID : U54 EB020403
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA047119
Pays : United States
Organisme : NIDA NIH HHS
ID : 1R01DA047119-01
Pays : United States
Organisme : NIH HHS
ID : U54 EB 020403
Pays : United States
Informations de copyright
© 2020 The Authors. Human Brain Mapping published by Wiley Periodicals LLC.
Références
Bull World Health Organ. 2004 Nov;82(11):858-66
pubmed: 15640922
Mol Psychiatry. 2016 Apr;21(4):547-53
pubmed: 26033243
Alcohol Clin Exp Res. 2009 Apr;33(4):740-50
pubmed: 19170662
J Comput Assist Tomogr. 1989 May-Jun;13(3):395-8
pubmed: 2723168
Nat Genet. 2012 Apr 15;44(5):552-61
pubmed: 22504417
Hum Brain Mapp. 2022 Jan;43(1):399-413
pubmed: 32643841
Biol Psychiatry. 2016 Apr 1;79(7):549-56
pubmed: 26386480
Psychol Med. 2014 Oct;44(13):2787-98
pubmed: 25066449
Br J Radiol. 2019 Sep;92(1101):20180942
pubmed: 30855982
Lancet. 2013 Nov 9;382(9904):1575-86
pubmed: 23993280
PLoS One. 2013 Oct 24;8(10):e76635
pubmed: 24204649
Br Med Bull. 1994 Jan;50(1):99-114
pubmed: 8149203
Cereb Cortex. 2013 Jan;23(1):97-104
pubmed: 22275479
Neuropsychopharmacology. 2005 Feb;30(2):423-32
pubmed: 15562292
Neurobiol Stress. 2018 Sep 27;10:100132
pubmed: 30627600
Neuroimage Clin. 2013 Apr 01;2:469-76
pubmed: 24179800
Psychol Med. 2014 Jun;44(8):1713-25
pubmed: 24016382
Addict Biol. 2014 Jul;19(4):722-32
pubmed: 23311613
Eur Arch Psychiatry Clin Neurosci. 2019 Feb;269(1):59-71
pubmed: 30706169
Mol Psychiatry. 2018 Apr;23(4):932-942
pubmed: 28461699
Psychopharmacology (Berl). 2016 Oct;233(19-20):3627-37
pubmed: 27503373
Psychol Med. 2011 Nov;41(11):2349-59
pubmed: 21466751
Psychiatry Res. 2012 Nov 30;204(2-3):101-11
pubmed: 23149031
J Stud Alcohol. 1984 Jan;45(1):1-9
pubmed: 6366376
Drug Alcohol Depend. 2012 Jul 1;124(1-2):142-8
pubmed: 22270405
Addict Biol. 2013 May;18(3):570-80
pubmed: 22264344
Lancet. 2012 Dec 15;380(9859):2095-128
pubmed: 23245604
Mol Psychiatry. 2017 Jun;22(6):900-909
pubmed: 27137745
J Child Psychol Psychiatry. 2017 Dec;58(12):1360-1369
pubmed: 28677235
Addict Biol. 2017 Nov;22(6):1562-1575
pubmed: 27594419
Handb Clin Neurol. 2014;125:275-90
pubmed: 25307581
Alcohol Clin Exp Res. 2002 Apr;26(4):558-64
pubmed: 11981133
Lancet Psychiatry. 2017 Apr;4(4):310-319
pubmed: 28219628
Am J Drug Alcohol Abuse. 2018;44(1):4-18
pubmed: 28498718
Neuropsychopharmacology. 2014 Aug;39(9):2041-8
pubmed: 24633558
Arch Gen Psychiatry. 2008 Jun;65(6):694-701
pubmed: 18519827
Addiction. 2018 Oct;113(10):1905-1926
pubmed: 29749059
Transl Psychiatry. 2016 Jan 12;6:e710
pubmed: 26756903
Radiology. 1993 Jan;186(1):59-65
pubmed: 8416587
Drug Alcohol Depend. 2015 Aug 1;153:22-8
pubmed: 26072220
Cortex. 2003 Sep-Dec;39(4-5):1027-45
pubmed: 14584565
J Stud Alcohol. 2001 Jul;62(4):533-42
pubmed: 11513232
Brain Imaging Behav. 2014 Jun;8(2):153-82
pubmed: 24399358
Drug Alcohol Depend. 2005 Jan 7;77(1):23-30
pubmed: 15607838
Brain. 2012 Jul;135(Pt 7):2245-55
pubmed: 22669080
Alcohol Res Health. 2003;27(2):146-52
pubmed: 15303625
Neuroimage. 2007 Jul 15;36(4):1065-73
pubmed: 17513132
Am J Drug Alcohol Abuse. 2013 Nov;39(6):372-81
pubmed: 24200207
Front Psychiatry. 2019 Oct 23;10:702
pubmed: 31708805
Drug Alcohol Rev. 2007 Jan;26(1):25-31
pubmed: 17364833
Hum Brain Mapp. 2014 May;35(5):2470-82
pubmed: 24038570
J Psychiatr Res. 2011 Aug;45(8):1055-66
pubmed: 21296361
Trends Mol Med. 2006 Dec;12(12):559-66
pubmed: 17070107
Brain. 2015 Jan;138(Pt 1):69-79
pubmed: 25367022
Neuropsychologia. 2003;41(7):773-82
pubmed: 12631528
Psychopharmacology (Berl). 2005 Aug;180(4):583-94
pubmed: 15834536
Addict Biol. 2020 Nov;25(6):e12830
pubmed: 31746534
J Stud Alcohol. 1998 Mar;59(2):180-90
pubmed: 9500305
PLoS One. 2013;8(2):e55821
pubmed: 23390554
J Stud Alcohol. 1980 Mar;41(3):325-37
pubmed: 7374149
Neuroimage. 2012 Feb 15;59(4):3845-51
pubmed: 21982932
Front Neuroinform. 2014 May 21;8:54
pubmed: 24904400
Neurosci Biobehav Rev. 2016 Jul;66:92-103
pubmed: 27108216
Drug Alcohol Depend. 2014 Sep 1;142:204-8
pubmed: 25012896
Schizophr Res. 2013 Jan;143(1):179-84
pubmed: 23201308
Alcohol Clin Exp Res. 1998 Jun;22(4):954-61
pubmed: 9660328
J Psychiatr Res. 2014 Apr;51:68-78
pubmed: 24411594
Neuropsychopharmacology. 2012 Jul;37(8):1923-33
pubmed: 22534625
Front Psychol. 2013 Nov 26;4:863
pubmed: 24324449
Br J Psychiatry. 2015 Jan;206(1):77-8
pubmed: 25431432
Mol Psychiatry. 2016 Dec;21(12):1710-1716
pubmed: 26857596
Addict Biol. 2015 Sep;20(5):979-89
pubmed: 25477246
Nature. 2015 Apr 9;520(7546):224-9
pubmed: 25607358
Int J Neurosci. 1980;10(2-3):99-105
pubmed: 7364547
Neuropsychopharmacology. 2009 Oct;34(11):2450-8
pubmed: 19553917
Neuron. 2002 Jan 31;33(3):341-55
pubmed: 11832223
Lancet. 2015 Nov 28;386(10009):2145-91
pubmed: 26321261
Psychiatry Clin Neurosci. 2013 Nov;67(7):483-92
pubmed: 24118193
Am J Psychiatry. 2019 Feb 1;176(2):119-128
pubmed: 30336705
Hum Brain Mapp. 2011 Nov;32(11):1998-2013
pubmed: 21162046
Psychiatry Res. 2013 Oct 30;214(1):1-8
pubmed: 23916536
J Stud Alcohol Drugs. 2007 Nov;68(6):886-95
pubmed: 17960307
Biol Psychiatry. 2018 Nov 1;84(9):644-654
pubmed: 29960671
Addict Biol. 2017 Jul;22(4):1036-1047
pubmed: 26934839